- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05436509
CD19/79b Bi-specific CAR-T Cell Therapy
CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with refractory and/or recurrent B cell malignancies have poor prognosis despite complex multimodal therapy. Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Further, more than 40% patients with progressive large B cell lymphoma (LBCL) experienced reduced or lost expression of CD19 on the tumor cells after CAR19 treatment; low surface CD19 density before treatment was associated with progressive disease. Therefore, novel curative approaches are needed. The investigation attempts to use genetically modified T cells to express a 4th generation lentiviral anti-CD19/79b bi-specific CAR (bi-4SCAR-CD19/79b). The CAR molecules enable the T cells to recognize and kill tumor cells through the recognition of a surface antigen, CD19 or CD79b, which is expressed at high levels on tumor cells but not at significant levels on normal tissues.
CD79b is a B cell surface antigen, which is a component of B cell receptor. CD79b is up-regulated in more than 90% of B-cell lymphomas. Recent studies have shown that CD79b CAR-T cells have potential in targeting B-cell lymphomas. In addition, several immunotherapy drugs based on targeting CD79b have been reported worldwide. The CD79b specific CAR-T cells with binding moiety of CD79b specific scFv exhibited a high affinity and antitumor effect against CD79b+ tumor cells.
A potential strategy to prevent relapse due to antigen escape is to infuse T-cells capable of recognizing multiple antigens. To overcome tumor escape of single target antigen and enhance in vivo CAR-T efficacy, a novel bi-specific CD19/79b CAR-T therapy regimen is developed to include booster and consolidation CAR-T applications to target highly-refractory B cell cancer. The aim is to evaluate safety and long term efficacy of the bi-CAR-T therapy strategy in CD19 and/or CD79b positive cancer patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- Recruiting
- Shenzhen Geno-Immune Medical Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age older than 6 months.
- malignant B cell surface expression of CD19 or CD79b molecules.
- the KPS score over 80 points, and survival time is more than 1 month.
- greater than Hgb 80 g/L.
- no contraindications to blood cell collection.
Exclusion Criteria:
- accompanied with other active diseases and difficult to assess patient response.
- bacterial, fungal, or viral infection, unable to control.
- living with HIV.
- active HBV or HCV infection.
- pregnant and nursing mothers.
- under systemic steroid treatment within a week of the treatment.
- prior failed CD19 and CD79b CAR-T treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: bi-4SCAR-CD19/79b T Cell Therapy for CD19 and/or CD79b positive B cell malignancies
|
Infusion of bi-4SCAR-CD19/79b T cells at 10^6 cells/kg body weight via IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of fourth generation bi-4SCAR-CD19/79b T cells in patients with B cell malignancies
Time Frame: 12 weeks
|
Safety of fourth generation bi-4SCAR-CD19/79b T cells in patients with B cell malignancies using CTCAE 4 standard to evaluate the level of adverse events standard to evaluate the level of adverse events
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti tumor activity of fourth generation bi-4SCAR-CD19/79b T cells in patients with relapsed or refractory B cell malignancies
Time Frame: 1 year
|
Scale of CAR copies (for efficacy)
|
1 year
|
Anti tumor activity of fourth generation bi-4SCAR-CD19/79b T cells in patients with relapsed or refractory B cell malignancies
Time Frame: 1 year
|
Scale of leukemic cell burden (for efficacy)
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIMI-IRB-22009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B Cell Malignancies
-
Beijing InnoCare Pharma Tech Co., Ltd.Active, not recruitingPart 1:r/r B-cell Malignancies | Part 2:B-cell MalignanciesUnited States, Poland, Israel, Ukraine
-
TransThera Sciences (Nanjing), Inc.RecruitingB-Cell MalignanciesChina
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Incyte CorporationCompleted
-
BeiGeneCompletedB-cell MalignanciesUnited States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.Unknown
-
Shanghai Tongji Hospital, Tongji University School...Recruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Gilead SciencesActive, not recruitingB-cell MalignanciesUnited States, United Kingdom, France
Clinical Trials on bi-4SCAR CD19/79b T cells
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Peking UniversityUniversity of FloridaUnknown
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
Shenzhen Geno-Immune Medical InstituteThe Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaboratorsRecruiting
-
Shenzhen Geno-Immune Medical InstituteThe Seventh Affiliated Hospital of Sun Yat-sen UniversityRecruiting
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina